Vital Therapies (NASDAQ:VTL)‘s stock had its “buy” rating reissued by Raymond James Financial in a research report issued to clients and investors on Tuesday.

VTL has been the topic of a number of other research reports. Zacks Investment Research lowered Vital Therapies from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. ValuEngine lowered Vital Therapies from a “sell” rating to a “strong sell” rating in a research report on Friday, November 17th. Finally, BidaskClub lowered Vital Therapies from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $8.00.

Shares of Vital Therapies (VTL) traded up $0.15 on Tuesday, hitting $4.80. The stock had a trading volume of 140,900 shares, compared to its average volume of 147,791. Vital Therapies has a one year low of $2.25 and a one year high of $6.50.

Vital Therapies (NASDAQ:VTL) last issued its quarterly earnings results on Wednesday, October 25th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.02. During the same period in the prior year, the business posted ($0.32) earnings per share. sell-side analysts expect that Vital Therapies will post -1.26 earnings per share for the current year.

In related news, Director Jean Jacques Bienaime purchased 10,000 shares of Vital Therapies stock in a transaction on Wednesday, September 13th. The shares were purchased at an average price of $4.00 per share, for a total transaction of $40,000.00. Following the transaction, the director now owns 65,119 shares of the company’s stock, valued at approximately $260,476. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Muneer A. Satter purchased 130,000 shares of Vital Therapies stock in a transaction on Thursday, September 14th. The stock was bought at an average price of $4.01 per share, for a total transaction of $521,300.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 190,000 shares of company stock worth $737,800 in the last 90 days. 32.60% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in VTL. Dimensional Fund Advisors LP acquired a new position in shares of Vital Therapies in the 3rd quarter valued at about $116,000. JPMorgan Chase & Co. lifted its stake in shares of Vital Therapies by 1,985.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 25,462 shares of the company’s stock valued at $123,000 after purchasing an additional 24,241 shares during the period. New York State Common Retirement Fund acquired a new position in shares of Vital Therapies in the 3rd quarter valued at about $213,000. Dowling & Yahnke LLC acquired a new position in shares of Vital Therapies in the 3rd quarter valued at about $252,000. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Vital Therapies by 1.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock valued at $258,000 after purchasing an additional 1,157 shares during the period. 24.35% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/06/vital-therapies-vtl-earns-buy-rating-from-raymond-james-financial.html.

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.